Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment

Abstract excerpt

In the last decade, many small molecules, usually characterized by heterocyclic scaffolds, have been designed and synthesized as tyrosine kinase inhibitors (TKIs). Among them, several compounds have been tested at preclinical and clinical levels to treat glioblastoma multiforme (GBM). GBM is the most common and aggressive type of cancer originating in the brain and has an unfavorable prognosis, with a median...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Lung Cancer Treatments and Mutations
• Share to Melanoma and MAPK Pathways